The takeaways appear to be:
- Final MM Phase 2 data finally was reported in 2012,
- Murine study data, via Moffitt, showed PV-10's systemic, anti-tumor immune response,
- This systemic immune response was shown in multiple cancers (i.e., melanoma, lung, breast),
- Combination therapy complementariness of PV-10 and "ipi," and
- Potentially year-end completion for the expanded HCC Phase 1 trial.
A question: Will Dr. Rosemurgy be the PI for a pancreas P1 trial?